Novavax Overview

  • Year Founded
  • 1987

Year Founded

  • Status
  • Public

  • Employees
  • 749

Employees

  • Stock Symbol
  • NVAX

Stock Symbol

  • Investments
  • 4

  • Share Price
  • $8.53
  • (As of Friday Closing)

Novavax General Information

Description

Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. It works together with its wholly owned Swedish subsidiary to produce vaccine candidates to respond to both known and emerging disease threats. The company believes its vaccine technology has the potential to be applied broadly to a wide variety of human infectious diseases. The company manages its business as one operating segment, an in-house early-stage R&D business to build a pipeline of high-value assets using its technology along with seeking to enter into partnerships to drive value creation for its assets.

Contact Information

Website
www.novavax.com
Ownership Status
Publicly Held
Financing Status
Corporation
Corporate Office
  • 21 Firstfield Road
  • Gaithersburg, MD 20878
  • United States
+1 (240)
Primary Industry
Pharmaceuticals
Other Industries
Drug Discovery
Biotechnology
Stock Exchange
NAS
Vertical(s)
Corporate Office
  • 21 Firstfield Road
  • Gaithersburg, MD 20878
  • United States
+1 (240)

Novavax Timeline

2023202420252026
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Novavax Stock Performance

As of 13-Nov-2026, Novavax’s stock price is $8.53. Its current market cap is $1.41B with 165M shares.

(As of Friday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$8.53 $8.76 $6.20 - $13.38 $1.41B 165M 6.76M -$0.46

Novavax Financials Summary

As of 30-Sep-2026, Novavax has a trailing 12-month revenue of $412M.

In Thousands,
USD
TTM 30-Sep-2026 FY 2025 31-Dec-2025 FY 2024 31-Dec-2024 FY 2023 31-Dec-2023
EV 1,361,042 580,239 611,664 141,200
Revenue 411,649 1,123,479 682,162 556,382
EBITDA (35,828) 492,327 (108,044) (487,390)
Net Income (76,727) 440,302 (187,499) (545,062)
Total Assets 888,005 1,176,512 1,560,418 1,797,490
Total Debt 295,263 248,811 230,419 229,081
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Novavax Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Novavax‘s full profile, request access.

Request a free trial

Novavax Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development wi
Pharmaceuticals
Gaithersburg, MD
749 As of 2025

Emeryville, CA
 

Cambridge, MA
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Novavax Competitors (44)

One of Novavax’s 44 competitors is Dynavax Technologies, a Formerly VC-backed company based in Emeryville, CA.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Dynavax Technologies Formerly VC-backed Emeryville, CA
Moderna Formerly VC-backed Cambridge, MA
Valneva Formerly VC-backed Lyon, France
Cytodyn Formerly Angel backed Vancouver, WA
Sinovac Biotech Corporation Beijing, China
You’re viewing 5 of 44 competitors. Get the full list »

Novavax Patents

Novavax Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-20260345770-A1 Compositions and methods for modulating immune response Pending 14-Apr-2025
WO-2026222087-A2 Compositions and methods for modulating immune response Pending 14-Apr-2025
US-20260294831-A1 Protein-based drug products using monoester-free polysorbate detergent Pending 28-Mar-2025
WO-2026202855-A1 Protein-based drug products using monoester-free polysorbate detergent Pending 28-Mar-2025
US-20260259196-A1 Assays for the evaluation of seasonal covid-influenza combination vaccines Pending 07-Feb-2025 G01N33/5023
To view Novavax’s complete patent history, request access »

Novavax Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Novavax Investments & Acquisitions (4)

Novavax’s most recent deal was a Merger/Acquisition with Novavax CZ for . The deal was made on 27-May-2020.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Novavax CZ 27-May-2020 Merger/Acquisition Biotechnology
Novavax (Maryland) 22-Aug-2013 Merger/Acquisition Other Commercial Products
CPL Biologicals 01-Jan-2009 Joint Venture Other Devices and Supplies
Nanotherapeutics Merger/Acquisition Pharmaceuticals
To view Novavax’s complete investments and acquisitions history, request access »

Novavax ESG

Risk Overview

Risk Rating

Updated November, 04, 2026

25.81 | Med Risk

Risk Scale

A lower score indicates better sustainability

Negl

0-10

Low

10-20

Med

20-30

High

30-40

Severe

40+

Exposure

Exposure refers to the extent to which a company is exposed to different material ESG issues

Management

Management is related to actions taken to manage ESG issues

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

of 13,592

Rank

Percentile

Pharmaceuticals

Industry

of 852

Rank

Percentile

Biotechnology

Subindustry

of 431

Rank

Percentile

To view Novavax’s complete esg history, request access »

Novavax Exits (1)

Novavax’s most recent exit was on 27-May-2020 from Novavax CZ. The exit was categorized as .

Company Name Exit Date Exit Type Exit Size Status Buyers
Novavax CZ 27-May-2020 Completed
To view Novavax’s complete exits history, request access »

Novavax FAQs

  • When was Novavax founded?

    Novavax was founded in 1987.

  • Where is Novavax headquartered?

    Novavax is headquartered in Gaithersburg, MD.

  • What is the size of Novavax?

    Novavax has 749 total employees.

  • What industry is Novavax in?

    Novavax’s primary industry is Pharmaceuticals.

  • Is Novavax a private or public company?

    Novavax is a Public company.

  • What is Novavax’s stock symbol?

    The ticker symbol for Novavax is NVAX.

  • What is the current stock price of Novavax?

    As of 13-Nov-2026 the stock price of Novavax is $8.53.

  • What is the current market cap of Novavax?

    The current market capitalization of Novavax is $1.41B.

  • What is Novavax’s current revenue?

    The trailing twelve month revenue for Novavax is $412M.

  • Who are Novavax’s competitors?

    Dynavax Technologies, Moderna, Valneva, Cytodyn, and Sinovac Biotech are some of the 44 competitors of Novavax.

  • What is Novavax’s annual earnings per share (EPS)?

    Novavax’s EPS for 12 months was -$0.46.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process